Sequenom expects to "significantly exceed" its internal goal of billing for 50,000 MaterniT21 Plus LDT non-invasive prenatal fetal tests this year, following strong sales of the test in the third quarter and endorsements of non-invasive prenatal testing by two technology assessment committees.

Last week, the company reported that its laboratory, the Sequenom Center for Molecular Medicine, received 18,000 MaterniT21 Plus test samples during the third quarter, and 37,000 during the first year since the test's launch in the fall of 2011.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.

Jul
14
Sponsored by
Agilent Technologies

This online seminar will outline a recent example of the use of molecular barcoding in combination with next-generation sequencing to detect somatic mosaicism in cancer patients.